Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

What is next, and who is running it?

Programs by company or class, across phase, filing, approval, and a stop.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

14 of 17 programs on this matrix

Phase 2Phase 3FiledApprovedDiscontinued
Asan Medical Center1 program
Ascentage Pharma1 program
Bayer1 program
Regorafenib

Approved

once daily, days 1 to 21 of 28, oral tablet

multi-kinase TKI · Bayer

Blueprint Medicines1 program
Avapritinib

Approved

once daily, oral tablet

KIT/PDGFRA type I TKI · Blueprint Medicines

Centre Leon Berard1 program
Cogent Biosciences1 program
Deciphera Pharmaceuticals2 programs
DCC-3009

Registry, May 2028

Dosing n/r

Class not reported · Deciphera Pharmaceuticals

Ripretinib

Registry, Dec 2027

once daily, oral tablet

switch-control KIT/PDGFRA TKI · Deciphera Pharmaceuticals

GSK1 program
Merck1 program
Ningbo Newbay Technology Development1 program
NB003

Registry, Aug 2028

twice daily, oral

selective KIT TKI · Ningbo Newbay Technology Development

Novartis1 program
Peking University1 program
Pfizer1 program
Sunitinib

Approved

once daily, Schedule 4/2, oral capsule

multi-kinase TKI (type II) · Pfizer